# The Effect of Dialysate Bicarbonate Concentration or Oral Bicarbonate Supplementation on Outcomes in Patients on Maintenance Dialysis: A Systematic Review and Meta-Analysis

**Authors:** Ashlee M. Azizudin, Samuel A. Silver, Amit X. Garg, Zoe K. Friedman, Andrea C. Cowan, Catherine M. Clase, Amber O. Molnar

PMC · DOI: 10.1177/20543581251356182 · Canadian Journal of Kidney Health and Disease · 2025-07-31

## TL;DR

This study reviews whether adjusting dialysis bicarbonate levels or using oral supplements improves health outcomes for dialysis patients, finding limited evidence due to small and inconsistent studies.

## Contribution

The study systematically evaluates the clinical impact of dialysate bicarbonate concentration and oral supplementation on dialysis patients, highlighting the lack of robust evidence from randomized trials.

## Key findings

- Meta-analysis found a 3.5 mmol/L increase in pre-dialysis serum bicarbonate with higher dialysate concentrations.
- Most studies showed no significant differences in mortality, hospitalizations, or nutritional outcomes.
- Evidence remains uncertain due to small study sizes and high heterogeneity.

## Abstract

Metabolic acidosis is a common complication of kidney failure that is treated with bicarbonate supplementation. The addition of bicarbonate to the dialysis solution and oral bicarbonate supplementation are used to treat metabolic acidosis in patients receiving dialysis, but the treatment approach that is best for patient health remains unknown.

The purpose of this study was to determine whether the concentration of dialysate bicarbonate or the use of oral bicarbonate supplementation alters the risk of mortality, hospitalizations, cardiovascular and nutritional outcomes, and laboratory measurements in patients treated with maintenance dialysis.

Systematic review and meta-analysis.

Any country of origin.

Adult patients (≥18 years) receiving maintenance dialysis.

Extracted data included demographic characteristics and outcomes such as mortality, hospitalizations, cardiovascular events, surrogate markers of nutrition, and pre-dialysis and post-dialysis levels of serum bicarbonate, pH, calcium, potassium, and parathyroid hormone.

We searched MEDLINE, Embase, CENTRAL, and Google Scholar through October 7, 2024 for studies examining dialysate bicarbonate concentration and/or oral bicarbonate supplementation in adults undergoing maintenance dialysis. Meta-analysis was performed for pre-dialysis serum bicarbonate and for pre-dialysis and post-dialysis calcium and potassium.

We identified 37 studies (n = 24,782 patients) with patients treated with hemodialysis (13 randomized trials, 10 non-randomized interventional studies, 14 observational studies) and 4 studies (n = 347 patients) with patients receiving peritoneal dialysis (3 randomized trials, 1 non-randomized interventional study). No randomized trials reported mortality or hospitalizations in hemodialysis patients. Studies reporting cardiovascular outcomes (n = 20) were small with inconsistent results. Most studies reporting nutritional outcomes (n = 21) reported no significant differences with dialysate bicarbonate concentration or oral bicarbonate supplementation but were small in sample size (largest study n = 200). Meta-analysis of parallel-group randomized trials comparing dialysate bicarbonate >35 mmol/L with ≤35 mmol/L found a mean difference of 3.5 mmol/L (95% confidence interval [CI] −0.6 to 7.7) in pre-dialysis serum bicarbonate.

Non-English and gray literature were excluded. Most studies were small or observational in nature, and heterogeneity further limited the ability to perform meta-analysis of outcomes such as mortality, hospitalizations, and cardiovascular outcomes.

The evidence for the effect of higher vs lower dialysate bicarbonate concentration and oral bicarbonate supplementation on clinical outcomes in dialysis patients is very uncertain. There is a need for large, high-quality randomized controlled trials in this area.

## Linked entities

- **Chemicals:** bicarbonate (PubChem CID 769)
- **Diseases:** metabolic acidosis (MONDO:0000440), kidney failure (MONDO:0001106)

## Full-text entities

- **Genes:** PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}
- **Diseases:** kidney failure (MESH:D051437), Metabolic acidosis (MESH:D000138)
- **Chemicals:** Dialysate Bicarbonate (-), Bicarbonate (MESH:D001639), calcium (MESH:D002118), potassium (MESH:D011188)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12317238/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12317238/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12317238/full.md

---
Source: https://tomesphere.com/paper/PMC12317238